Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.

Scientific reports - 1 Dec 2016

Guffanti F, Fruscio R, Rulli E, Damia G

Abstract excerpt

Late stage epithelial ovarian cancer has a dismal prognosis. Identification of pharmacogenomic markers (i.e. polymorphisms) to stratify patients to optimize individual therapy is of paramount importance. We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 1

Share to Checkpoint Kinase 2

Share to Cyclin-Dependent Kinases

Share to Disease-Free Survival

Share to Neoplasms, Glandular and Epithelial

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 27905519
DOI: 10.1038/srep38142
PMCID: PMC5131275

Genes

CDK12
ATM
ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.PMID 27905519Read ↗

Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy.Semantic proximity Read ↗

Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.Semantic proximity Read ↗

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersSemantic proximity Read ↗

Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Semantic proximity Read ↗

The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.Semantic proximity Read ↗

DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.Semantic proximity Read ↗

DNA repair and response to therapy : exploring their relation in epithelial ovarian cancer modelsSemantic proximity Read ↗

The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.Semantic proximity Read ↗

Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.